Literature DB >> 34034786

VITADIAL "Does correction of 25 OH-VITAmin D with cholecalciferol supplementation increase muscle strength in hemoDIALysis patients?": study protocol for a randomized controlled trial.

Stanislas Bataille1,2,3, Nathalie Pedinielli4, Elisa Carreno4, Mathilde Prezelin-Reydit5, Philippe Chauveau5, Guillaume Jean6, Thomas Robert7, Mickaël Bobot8,7, Guillaume Seret9, Elisabeth Jouve10, Frederic Lavainne11, Marianne Serveaux4,12,13, Laurence Vrigneaud14, Stéphanie Gentile10.   

Abstract

BACKGROUND: Muscle strength decreases as kidney failure progresses. Low muscle strength affects more than 50% of hemodialysis patients and leads to daily life activities impairment. In the general population, numerous studies have linked low 25OH-vitamin D (25OHD) concentrations to the loss of the muscle strength and low physical performances. Data on native vitamin D and muscle function are scarce in the chronic kidney disease (CKD) population, but low 25OHD levels have been associated with poor muscle strength. We present in this article the protocol of an ongoing study named VITADIAL testing if cholecalciferol supplementation in hemodialysis patients with low 25OHD improves their muscle strength. METHODS/
DESIGN: VITADIAL is a prospective open randomized French multicenter study. All patients will have 25OHD levels ≤50nmol/L at randomization. One group will receive 100,000 UI cholecalciferol once a month during 6 months; the other group will receive no treatment during 6 months. In order to randomize patients with 25OHD ≤50nmol/L, supplemented patients will undergo a 3 months wash-out period renewable 3 times (maximum of 12 months wash-out) until 25OHD reaches a level ≤50nmol/L. The main objective of this study is to analyze if a 6-month period of oral cholecalciferol (i.e., native vitamin D) supplementation improves muscle strength of hemodialysis patients with low 25OHD vitamin D levels. Muscle strength will be assessed at 0, 3, and 6 months, by handgrip strength measured with a quantitative dynamometer. Secondary objectives are (1) to analyze 25OHD plasma levels after vitamin D wash-out and/or supplementation, as well as factors associated with 25OHD lowering speed during wash-out, and (2) to analyze if this supplementation improves patient's autonomy, reduces frailty risk, and improves quality of life. Fifty-four patients are needed in each group to meet our main objective. DISCUSSION: In the general population, around 30 randomized studies analyzed the effects of vitamin D supplementation on muscle strength. These studies had very different designs, sizes, and studied population. Globally, these studies and the meta-analysis of studies favor a beneficial effect of vitamin D supplementation on muscle strength, but this effect is mainly found in the subgroup of aged patients and those with the lowest 25OHD concentrations at inclusion. We reported a positive independent association between 25OHD and handgrip strength in a population of 130 hemodialysis patients in a dose-dependent manner. In our cohort, a plateau effect was observed above 75 nmol/L. Only two randomized studies analyzed the effect of native vitamin D supplementation on muscle strength in hemodialysis patients, but unfortunately, these two studies were underpowered. VITADIAL is a trial specifically designed to assess whether cholecalciferol might benefit to hemodialysis patient's muscle strength. TRIAL REGISTRATION: ClinicalTrials.gov NCT04262934 . Registered on 10 February 2020 - Retrospectively registered.

Entities:  

Year:  2021        PMID: 34034786     DOI: 10.1186/s13063-021-05302-9

Source DB:  PubMed          Journal:  Trials        ISSN: 1745-6215            Impact factor:   2.279


  41 in total

Review 1.  Physical functioning in end-stage renal disease patients: update 2005.

Authors:  Patricia Painter
Journal:  Hemodial Int       Date:  2005-07       Impact factor: 1.812

2.  Body composition and survival in dialysis patients: results from an international cohort study.

Authors:  Daniele Marcelli; Len A Usvyat; Peter Kotanko; Inga Bayh; Bernard Canaud; Michael Etter; Emanuele Gatti; Aileen Grassmann; Yuedong Wang; Cristina Marelli; Laura Scatizzi; Andrea Stopper; Frank M van der Sande; Jeroen Kooman
Journal:  Clin J Am Soc Nephrol       Date:  2015-04-21       Impact factor: 8.237

3.  [Neuropathies, myopathies and neuromyopathies in chronic uremic patients].

Authors:  G Serratrice; M Toga; H Roux; A Murisasco; G de Bisschop
Journal:  Presse Med       Date:  1967-09-16       Impact factor: 1.228

4.  The diagnosis of sarcopenia is mainly driven by muscle mass in hemodialysis patients.

Authors:  Stanislas Bataille; Marianne Serveaux; Elisa Carreno; Nathalie Pedinielli; Patrice Darmon; Alain Robert
Journal:  Clin Nutr       Date:  2016-10-22       Impact factor: 7.324

Review 5.  Physical functioning and exercise capacity in patients on dialysis.

Authors:  K L Johansen
Journal:  Adv Ren Replace Ther       Date:  1999-04

6.  Physiological abnormalities of skeletal muscle in dialysis patients.

Authors:  I H Fahal; G M Bell; J M Bone; R H Edwards
Journal:  Nephrol Dial Transplant       Date:  1997-01       Impact factor: 5.992

7.  Morphologic features of the myopathy associated with chronic renal failure.

Authors:  W Diesel; M Emms; B K Knight; T D Noakes; C R Swanepoel; R van Zyl Smit; R O Kaschula; C C Sinclair-Smith
Journal:  Am J Kidney Dis       Date:  1993-11       Impact factor: 8.860

8.  Progressive decline in renal function induces a gradual decrease in total hemoglobin and exercise capacity.

Authors:  N Clyne; T Jogestrand; L E Lins; S K Pehrsson
Journal:  Nephron       Date:  1994       Impact factor: 2.847

9.  Quality over quantity? Association of skeletal muscle myosteatosis and myofibrosis on physical function in chronic kidney disease.

Authors:  Thomas J Wilkinson; Douglas W Gould; Daniel G D Nixon; Emma L Watson; Alice C Smith
Journal:  Nephrol Dial Transplant       Date:  2019-08-01       Impact factor: 5.992

10.  Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction.

Authors:  Yuki Enoki; Hiroshi Watanabe; Riho Arake; Rui Fujimura; Kana Ishiodori; Tadashi Imafuku; Kento Nishida; Ryusei Sugimoto; Saori Nagao; Shigeyuki Miyamura; Yu Ishima; Motoko Tanaka; Kazutaka Matsushita; Hirotaka Komaba; Masafumi Fukagawa; Masaki Otagiri; Toru Maruyama
Journal:  J Cachexia Sarcopenia Muscle       Date:  2017-06-12       Impact factor: 12.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.